All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Luspatercept for the treatment of myelofibrosis with anemia: Latest data from ACE-536-MF-001
Bookmark this article
|
Results of the phase II, open-label ACE-536-MF-001 trial (NCT03194542) were published in Blood Advances by Gerds et al.1 This study evaluated the efficacy and safety of luspatercept in patients with MF and anemia, including those with and without red blood cell transfusion dependence and concurrent JAKi therapy.1 |
| Key learnings |
|
Among non-transfusion dependent patients, 18.2% of patients without concurrent Rux and 21.4% with Rux experienced an anemia response, defined as a ≥1.5 g/dL Hb increase for 84 consecutive days without transfusion. |
|
Of all cohorts, the highest anemia response rates were observed in patients receiving concurrent Rux therapy, supporting the use of luspatercept in combination with JAKi to manage anemia in MF. |
|
Among patients who were transfusion-dependent, a reduction in dependance was observed in 47.6% without concurrent Rux and 52.6% with Rux. |
|
A reduction in TSS was observed across all cohorts, with the highest response in the cohort of patients who were not transfusion dependent and were treated with Rux. |
|
TRAE were observed in 47.4% of patients, with the most common being hypertension in 17.9%. There was one incidence of treatment discontinuation due to serious TRAE. |
|
There is an unmet need to reduce transfusion dependence in MF to enhance patient quality of life and healthcare resource utilization. |
|
These data support luspatercept as a feasible option for the treatment of anemia in patients with MF, reducing the need for transfusions and potentially allowing maintenance of JAKi therapy. A phase III trial of luspatercept in transfusion-dependent patients with MF receiving concomitant JAKi therapy is underway (INDEPENDENCE, ACE-536-MF-002). |
Abbreviations: Hb, hemoglobin; JAKi, Janus kinase inhibitor; MF, myelofibrosis; Rux, ruxolitinib; TRAE, treatment-related adverse events; TSS, total symptom score.
- Gerds A, Harrison C, Kiladjian J, et al. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis. Blood Advances. 2024;8(17):4511-4522. DOI: 1182/bloodadvances.2024012939
Your opinion matters
14 votes - 60 days left ...
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox